Premium
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
Author(s) -
Bringhen S.,
Milan A.,
D'Agostino M.,
Ferri C.,
Wäsch R.,
Gay F.,
Larocca A.,
Offidani M.,
Zweegman S.,
Terpos E.,
Goldschmidt H.,
Cavo M.,
Ludwig H.,
Driessen C.,
Auner H. W.,
Caers J.,
Gramatzki M.,
Dimopoulos M. A.,
Boccadoro M.,
Einsele H.,
Sonneveld P.,
Engelhardt M.
Publication year - 2019
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/joim.12882
Subject(s) - carfilzomib , medicine , multiple myeloma , adverse effect , intensive care medicine , hematology , oncology , proteasome inhibitor
Background The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies for relapsed and/or refractory multiple myeloma ( MM ) patients and produces impressive response rates in newly diagnosed MM as well. However, carfilzomib‐related cardiovascular adverse events ( CVAE s) – including hypertension (all grades: 12.2%; grade ≥3: 4.3%), heart failure (all grades: 4.1%; grade ≥3: 2.5%) and ischemic heart disease (all grades: 1.8%; grade ≥3: 0.8%) – may lead to treatment suspensions. At present, there are neither prospective studies nor expert consensus on the prevention, monitoring and treatment of CVAE s in myeloma patients treated with carfilzomib. Methods An expert panel of the European Myeloma Network in collaboration with the Italian Society of Arterial Hypertension and with the endorsement of the European Hematology Association aimed to provide recommendations to support health professionals in selecting the best management strategies for patients, considering the impact on outcome and the risk‐benefit ratio of diagnostic and therapeutic tools, thereby achieving myeloma response with novel combination approaches whilst preventing CVAE s. Results Patients scheduled to receive carfilzomib need a careful cardiovascular evaluation before treatment and an accurate follow‐up during treatment. Conclusions A detailed clinical assessment before starting carfilzomib treatment is essential to identify patients at risk for CVAE s, and accurate monitoring of blood pressure and of early signs and symptoms suggestive of cardiac dysfunction remains pivotal to safely administer carfilzomib without treatment interruptions or dose reductions.